Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.62 |
| ▸ | HTR1A | P08908 | 5/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.62 |
| ▸ | DRD1 | P21728 | 5/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.62 |
| ▸ | DRD3 | P35462 | 5/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754774 | 1.00 | CHRM2 (0.62) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Hydrochloric Acid SCHEMBL3712233 | 0.98 | CHRM2 (0.60) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Hydrochloric Acid SCHEMBL30722984 | 0.98 | CHRM2 (0.60) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL3377971 | 0.87 | CHRM2 (0.50) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL11032941 | 0.87 | CHRM2 (0.50) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL7349588 | 0.86 | CHRM2 (0.49) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Sulfuric Acid Diethyl Ester SCHEMBL7341452 | 0.85 | CHRM2 (0.48) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL7343953 | 0.85 | CHRM2 (0.48) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL9759318 | 0.84 | CHRM2 (0.47) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL9759321 | 0.84 | CHRM2 (0.47) | CHRM2HTR1AADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| EP-2007394-B1 | NOVEL USE OF ANTIHISTAMINE AGENTS FOR THE PREVENTIVE OR EARLY TREATMENT OF INFLAMMATORY SYNDROMES, IN PARTICULAR THOSE TRIGGERED BY TOGAVIRUSES | PF MEDICAMENT (FR) | 2012-10-10 | — | — | EP | claimed |
| US-8242110-B2 | Prevention of alphavirus caused arthritis with antihistamines such as alimemazine; antiserotonin agent and antihistamine combination therapy | PIERRE FABRE MEDICAMENT (FR) | 2012-08-14 | — | — | US | claimed |
| CN-102014625-A | Novel formulations for the treatment of migraine | ZOGENIX INC | 2011-04-13 | — | — | CN | claimed |
| US-20090325975-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-31 | — | — | US | claimed |
| CN-101394854-A | Novel use of antihistamine agents for the preventive or early treatment of inflammatory syndromes, in particular those triggered by togaviruses | PF MEDICAMENT (FR) | 2009-03-25 | — | — | CN | claimed |
| US-20090069308-A1 | Novel Use of Antihistamine Agents for the Preventive or Early Treatment of Inflammatory Syndromes, in Particular Those Triggered by Togaviruses | PIERRE FABRE MEDICAMENT (FR) | 2009-03-12 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-4833138-A | Phenothiazinealkaneamines for treatment of neurotoxic injury | WASHINGTON UNIVERSITY (US) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | CHRM2 2534/4885HTR1A 3268/4885ADRA2A 4228/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | CHRM2 315/4885HTR1A 1097/4885ADRA2A 2600/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CHRM2 531/4885HTR1A 1668/4885ADRA2A 3232/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | CHRM2 2594/4885HTR1A 3268/4885ADRA2A 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.